-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

Benzinga·10/30/2026 17:46:36
Listen to the news
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.